Journal of Lipid Research, Vol 34, 447-453, Copyright © 1993 by Lipid Research, Inc.

ARTICLES

Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma

S Fazio, Y Horie, KH Weisgraber, LM Havekes and SC Rall Jr
Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

Apolipoprotein (apo) E Leiden is a rare variant of human apoE characterized by defective receptor binding and associated with dominant transmission of type III hyperlipoproteinemia. In heterozygotes, apoE Leiden is present in higher concentrations in both total plasma and very low density lipoproteins (VLDL) than the other apoE allele product. In the present study we analyzed cell expression and plasma lipoprotein association of apoE Leiden to determine whether the unequal concentration of the two apoE allele products could be explained by differences in secretion rate from the hepatocyte or by preferential association with VLDL. We transfected the rat hepatoma cell line McA-RH7777 with apoE Leiden or normal human apoE3, and studied their secretion and media distribution. In pulse-chase experiments, the secretion of apoE Leiden was comparable to that of both human apoE3 and rat endogenous apoE, approaching 100% in 90 min. In similar transfection experiments, secreted apoE Leiden was significantly less glycosylated than normal apoE3 (21.7% vs. 36.6%, P < 0.005, n = 4), a finding also noted for apoE Leiden in human plasma. In in vitro incubation experiments, apoE Leiden showed a markedly higher preference for VLDL of normolipidemic human plasma when compared to both apoE3 (2.6-fold, P < 0.001) and apoE4 (1.6-fold, P < 0.001). These results suggest that the accumulation of apoE Leiden in VLDL derives from a high affinity of the mutant protein for the VLDL. This enrichment in defective apoE probably exacerbates impairment of VLDL removal from the circulation, thus contributing to the dominant transmission of type III hyperlipoproteinemia.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. W. Mahley, Y. Huang, and S. C. Rall , Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J. Lipid Res., November 1, 1999; 40(11): 1933 - 1949. [Abstract] [Full Text]

				A. H. Hasty, M. F. Linton, L. L. Swift, and S. Fazio Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance J. Lipid Res., August 1, 1999; 40(8): 1529 - 1538. [Abstract] [Full Text]

				A. H. Hasty, M. F. Linton, S. J. Brandt, V. R. Babaev, L. A. Gleaves, and S. Fazio Retroviral Gene Therapy in ApoE-Deficient Mice : ApoE Expression in the Artery Wall Reduces Early Foam Cell Lesion Formation Circulation, May 18, 1999; 99(19): 2571 - 2576. [Abstract] [Full Text] [PDF]

				C. A. Reardon, L. Blachowicz, K. M. Watson, E. Barr, and G. S. Getz Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells J. Lipid Res., July 1, 1998; 39(7): 1372 - 1381. [Abstract] [Full Text]

				L.-M. Dong, T. L. Innerarity, K. S. Arnold, Y. M. Newhouse, and K. H. Weisgraber The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity J. Lipid Res., June 1, 1998; 39(6): 1173 - 1180. [Abstract] [Full Text]

				P. H.E. Groot, B. J.M. van Vlijmen, G. M. Benson, M. H. Hofker, R. Schiffelers, M. Vidgeon-Hart, and L. M. Havekes Quantitative Assessment of Aortic Atherosclerosis in APOE*3 Leiden Transgenic Mice and Its Relationship to Serum Cholesterol Exposure Arterioscler. Thromb. Vasc. Biol., August 1, 1996; 16(8): 926 - 933. [Abstract] [Full Text]

				S. Fazio and Z. Yao The Enhanced Association of Apolipoprotein E With Apolipoprotein B–Containing Lipoproteins in Serum-Stimulated Hepatocytes Occurs Intracellularly Arterioscler. Thromb. Vasc. Biol., May 1, 1995; 15(5): 593 - 600. [Abstract] [Full Text]